MEP2108A - Kristalni sastav koji sadrži escitalopram - Google Patents

Kristalni sastav koji sadrži escitalopram

Info

Publication number
MEP2108A
MEP2108A MEP-21/08A MEP2108A MEP2108A ME P2108 A MEP2108 A ME P2108A ME P2108 A MEP2108 A ME P2108A ME P2108 A MEP2108 A ME P2108A
Authority
ME
Montenegro
Prior art keywords
composition containing
crystalline composition
containing escitalopram
escitalopram
crystalline particles
Prior art date
Application number
MEP-21/08A
Other languages
English (en)
Inventor
Troels Volsgaard Christensen
Ken Liljegren
Michiel Elema
Lene Andresen
Shashank Mahashabde
Sebastian P Assenza
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP2108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MEP2108A publication Critical patent/MEP2108A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Otkrivene su kristalne čestice escitalopram oksalata sa veličinom od bar 40 µm. Takođe je otkriven postupak za proizvodnju pomenutih kristalnih čestica i farmaceutskih sastava koji se sastoje od pomenutih kristalnih čestica.
MEP-21/08A 2001-07-31 2002-07-25 Kristalni sastav koji sadrži escitalopram MEP2108A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101164 2001-07-31
PCT/DK2002/000513 WO2003011278A1 (en) 2001-07-31 2002-07-25 Crystalline composition containing escitalopram

Publications (1)

Publication Number Publication Date
MEP2108A true MEP2108A (xx) 2010-02-10

Family

ID=8160647

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-21/08A MEP2108A (xx) 2001-07-31 2002-07-25 Kristalni sastav koji sadrži escitalopram

Country Status (39)

Country Link
US (3) US6916941B2 (bs)
EP (2) EP1522539B1 (bs)
JP (4) JP2005525993A (bs)
KR (1) KR20040028947A (bs)
CN (2) CN1660074A (bs)
AR (1) AR034898A1 (bs)
AT (2) ATE286730T1 (bs)
AU (1) AU2002355624B2 (bs)
BG (1) BG108571A (bs)
BR (1) BR0206164A (bs)
CA (1) CA2451915C (bs)
CO (1) CO5560540A2 (bs)
CY (1) CY1106413T1 (bs)
DE (2) DE60202615T2 (bs)
DK (2) DK1522539T3 (bs)
EA (1) EA006213B1 (bs)
EG (1) EG24206A (bs)
ES (2) ES2233842T3 (bs)
HR (2) HRP20031073A2 (bs)
HU (1) HUP0401946A2 (bs)
IL (2) IL159326A0 (bs)
IS (1) IS7077A (bs)
MA (1) MA27349A1 (bs)
ME (1) MEP2108A (bs)
MX (1) MXPA04000849A (bs)
MY (1) MY126238A (bs)
NO (1) NO328346B1 (bs)
NZ (1) NZ530157A (bs)
PE (1) PE20030304A1 (bs)
PL (1) PL366995A1 (bs)
PT (2) PT1414435E (bs)
RS (1) RS8304A (bs)
SI (1) SI1414435T1 (bs)
TN (1) TNSN04021A1 (bs)
TR (1) TR200400189T2 (bs)
UA (1) UA79930C2 (bs)
UY (1) UY27404A1 (bs)
WO (1) WO2003011278A1 (bs)
ZA (1) ZA200309684B (bs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514671A (en) 1999-04-14 2003-10-31 H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
HRP20031073A2 (en) * 2001-07-31 2004-04-30 Lundbeck & Co As H Crystalline composition containing escitalopram
AR040970A1 (es) 2002-08-12 2005-04-27 Lundbeck & Co As H Metodo para la separacion de intermediarios que pueden ser utilizados para la preparacion de escitalopram
TR200504022T1 (tr) * 2003-03-24 2006-08-21 Hetero Drugs Limited (S)-sitalopram oksalatın yeni sıvı kristal formları.
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
BRPI0508266A (pt) * 2004-03-05 2007-07-31 Lundbeck & Co As H partìculas cristalinas de oxalato de escitalopram, forma de dosagem única sólida, e, métodos para a fabricação de partìculas cristalinas de oxalato de escitalopram e para reduzir a quantidade de hidroxila que contém impurezas no citalopram, escitalopram ou uma mistura não racêmica de r- e s-citalopram
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
US20110196032A1 (en) * 2005-05-20 2011-08-11 Ashish Gogia Pharmaceutical Dosage Form of an Antidepressant
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
ATE398451T1 (de) * 2005-08-29 2008-07-15 Teva Pharma Festes, teilchenförmiges tadalafil mit bimodaler teilchengrössenverteilung
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
EP2086509A1 (en) * 2006-10-20 2009-08-12 Ratiopharm GmbH Escitalopram and solid pharmaceutical composition comprising the same
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
EP2291177A2 (en) * 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
ITMI20120448A1 (it) * 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
ITMI20120106A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Pastiglie liofilizzate di escitalopram ossalato per somministrazione sublinguale
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) * 2017-04-10 2018-10-18 東和薬品株式会社 エスシタロプラム医薬組成物
CN107441052A (zh) * 2017-06-21 2017-12-08 山东京卫制药有限公司 一种含有草酸艾司西酞普兰的片剂及其制备方法
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
JP7453859B2 (ja) * 2020-06-22 2024-03-21 東和薬品株式会社 エスシタロプラム錠剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (bs) * 1965-03-18
GB1358915A (en) 1971-09-13 1974-07-03 Merck & Co Inc Directly compressed tablet and composition therefor
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
WO1996041633A1 (en) 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
TR200000066T2 (tr) 1997-07-08 2000-11-21 H. Lundbeck A/S Sitalopram hazırlanması için yöntem.
GB9714841D0 (en) 1997-07-14 1997-09-17 Smithkline Beecham Plc Treatment method
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
UA62985C2 (en) 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
ES2149734T3 (es) 1997-11-11 2003-02-16 Lundbeck & Co As H Metodo para la preparacion de citalopram.
PL199423B1 (pl) 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
NZ514671A (en) 1999-04-14 2003-10-31 H Method for the preparation of citalopram
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
AU7405000A (en) * 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
HRP20031073A2 (en) * 2001-07-31 2004-04-30 Lundbeck & Co As H Crystalline composition containing escitalopram

Also Published As

Publication number Publication date
RS8304A (sr) 2006-12-15
EA200400243A1 (ru) 2004-06-24
CN1536997A (zh) 2004-10-13
NO20040380L (no) 2004-01-28
JP2011195591A (ja) 2011-10-06
ATE352546T1 (de) 2007-02-15
KR20040028947A (ko) 2004-04-03
SI1414435T1 (en) 2005-06-30
HRPK20080410B3 (en) 2009-09-30
DE60217932D1 (de) 2007-03-15
EP1522539B1 (en) 2007-01-24
HRP20080410A2 (en) 2008-10-31
ES2233842T3 (es) 2005-06-16
EP1414435A1 (en) 2004-05-06
JP2012211186A (ja) 2012-11-01
TR200400189T2 (tr) 2004-12-21
BG108571A (en) 2005-02-28
EA006213B1 (ru) 2005-10-27
MY126238A (en) 2006-09-29
IL159326A (en) 2010-05-31
BR0206164A (pt) 2003-10-28
ZA200309684B (en) 2004-12-22
DK1522539T3 (da) 2007-05-07
CY1106413T1 (el) 2011-10-12
HRP20031073A2 (en) 2004-04-30
US20080305164A1 (en) 2008-12-11
NO328346B1 (no) 2010-02-01
EP1522539A1 (en) 2005-04-13
TNSN04021A1 (en) 2006-06-01
US6916941B2 (en) 2005-07-12
US20030212128A1 (en) 2003-11-13
DE60202615D1 (de) 2005-02-17
ES2280892T3 (es) 2007-09-16
AR034898A1 (es) 2004-03-24
CA2451915A1 (en) 2003-02-13
CN1311819C (zh) 2007-04-25
DE60217932T2 (de) 2007-08-30
WO2003011278A1 (en) 2003-02-13
HUP0401946A2 (hu) 2005-01-28
JP2010150283A (ja) 2010-07-08
UY27404A1 (es) 2003-02-28
MXPA04000849A (es) 2004-05-14
EP1414435B1 (en) 2005-01-12
DK1414435T3 (da) 2005-05-09
EG24206A (en) 2008-10-21
IS7077A (is) 2003-12-15
JP5719811B2 (ja) 2015-05-20
PT1414435E (pt) 2005-05-31
ATE286730T1 (de) 2005-01-15
JP2005525993A (ja) 2005-09-02
JP5192568B2 (ja) 2013-05-08
MA27349A1 (fr) 2005-06-01
DE60202615T2 (de) 2006-01-12
CA2451915C (en) 2010-09-21
CN1660074A (zh) 2005-08-31
HK1070000A1 (en) 2005-06-10
AU2002355624B2 (en) 2006-02-02
PL366995A1 (en) 2005-02-07
IL159326A0 (en) 2004-06-01
NZ530157A (en) 2007-06-29
US7420069B2 (en) 2008-09-02
US20050147674A1 (en) 2005-07-07
CO5560540A2 (es) 2005-09-30
JP4971477B2 (ja) 2012-07-11
UA79930C2 (en) 2007-08-10
PE20030304A1 (es) 2003-03-27
PT1522539E (pt) 2007-03-30

Similar Documents

Publication Publication Date Title
MXPA04000849A (es) Composicion cristalina que contiene escitalopram.
AU2002303385A1 (en) High luminescence phosphor particles
AU2680000A (en) Cementitious compositions
WO2001098245A3 (en) Triphenyl compounds as interleukin-4 antagonists
HUP0500137A2 (en) Pyrrolidine-2-ones as factor xa inhibitors, process for producing them and pharmaceutical compositions containing the same
AU2002225369A1 (en) Photobase generators, curable compositions prepared by using the same and process of curing
AU2002219180A1 (en) Clay composition
AP2000001837A0 (en) Pharmaceutical compositions containing micronized bicyclic drugs.
WO2003080056A3 (en) Fine particle size pioglitazone
AU2003265265A1 (en) Process for coating ceramic particles and compositions formed from the same
EP1452812A4 (en) MELTING TAG FOR MELTING A RARE ALLOY ALLOY AND RARE ELEMENT ALLOY
AU2003273096A1 (en) Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
AU2003289165A1 (en) Calcium phosphate base particulate compound, process for producing the same and composition comprising the compound
AU2001279193A1 (en) Methods and compositions for the construction and use of viral envelops as display particles
AU2002347996A1 (en) Powdered epoxy composition
AU7773900A (en) Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds
AU2002251138A1 (en) Solid composition containing solid particles comprising at least one part fibres
SG159504A1 (en) Crystalline composition containing escitalopram oxalate
HK1027044A (en) Composition comprising finely divided, crystalline particles of budesonide
GB9822368D0 (en) Compositions for the entrapment of airborne particles
HU9801086D0 (en) New benzofurane derivatives, pharmaceutical compositions containing them as active component and process for producing the active component
AU2002330403A1 (en) Additive for cement composition and cement composition containing the same
AU2002341198A1 (en) Compositions comprising solid particles and binder
SI1240162T1 (en) Novel derivatives of 3-imino-1,2-dithioles, method for producing them and pharmaceutical compositions containing the same
AU2002310209A1 (en) Molding of materials from graphite particles